STOCK TITAN

Cullinan Oncology to Present at SVB Leerink’s 11th Annual Global Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

CAMBRIDGE, Mass., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) today announced that it will be participating in SVB Leerink’s 11th Annual Global Healthcare Conference, being held virtually February 14-18, 2022.

Nadim Ahmed, Cullinan’s Chief Executive Officer, will participate in a fireside chat on Thursday, February 17th at 8:40 a.m. ET

A live webcast of the fireside chat will be available via the Events section of the Company’s investor relations website at https://investors.cullinanoncology.com/news-events/events. Following the conclusion of the live event, an archive will be available for 30 days.

Management will also be participating in one-on-one investor meetings throughout the conference. Investors interested in scheduling a meeting with Cullinan’s management should contact their SVB Leerink representative.

About Cullinan Oncology
Cullinan Oncology is a biopharmaceutical company that is developing a diversified pipeline of targeted therapeutic candidates across multiple modalities in order to bring important medicines to cancer patients. The Company’s strategy is to source innovation through both internal discovery efforts and external collaborations, focusing on advanced stage assets with novel technology platforms and differentiated mechanisms. Learn more about Cullinan at www.cullinanoncology.com.

Contacts:

Investor Relations
Lee Roth
+1 212.213.0006
Lroth@burnsmc.com

Jeffrey Trigilio
+1 617.410.4650
jtrigilio@cullinanoncology.com

Media
Ariane Lovell
+1 917.565.2204
ariane.lovell@finnpartners.com


Cullinan Therapeutics, Inc.

NASDAQ:CGEM

CGEM Rankings

CGEM Latest News

CGEM Stock Data

1.19B
25.88M
6.4%
95.24%
3.33%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
CAMBRIDGE

About CGEM

cullinan oncology is focused on investing in and developing a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model. sourced from the cullinan dry lab as well as external collaborators, cullinan’s assets are managed by a single, highly experienced team of oncology professionals and drug developers across a lean, capital efficient operating model.